Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 2008

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 9C
Chunk 2008
---
  
    $22.68  
     8.98 

A
summary of the status of the Company’s nonvested options as of December 31, 2024, and 2023, and changes during years ended
December 31, 2024, and 2023, is presented below:

 Schedule
of nonvested options

    Non-vested Options 
    Options  
    Weighted- Average Exercise Price 

    Non-vested at December 31, 2023 
     113,429  
    $22.68 

    Granted 
     684,000  
    $1.26 

    Vested 
     (236,501) 
    $7.58 

    Forfeited 
     —  
    $— 

    Non-vested at December 31, 2024 
     560,928  
    $2.93 

    Non-vested Options 
    Options  
    Weighted- Average Exercise Price 

    Non-vested at December 31, 2022 
     45,556  
    $22.68 

    Granted 
     158,670  
    $22.68 

    Vested 
     (90,797) 
    $22.68 

    Forfeited 
     —  
    $— 

    Non-vested at December 31, 2023 
     113,429  
    $22.68 

The
total number of options granted during the years ended December 31, 2024 and 2023 was 684,000 and 158,670, respectively.
The exercise price for these options was $0.73, $1.30 or $22.68 per share. There was an intrinsic value of $0 and
$0 as of December 31, 2024 and 2023, respectively.

The
Company recognized stock-based compensation expense related to option vesting amortization of $1,455,561 and $1,733,233 for
the years ended December 31, 2024 and 2023, respectively, which is included in general and administrative expenses in the consolidated
statements of operations.

As
of December 31, 2024, the unamortized stock option expense was $1,